D3 Bio
Haopeng Rui serves as the Executive Director at D3 Bio, leading Translational Research and Biologics Discovery since March 2021. Prior experience includes a role as Senior Director at Johnson & Johnson from March 2017 to March 2021, where responsibility included overseeing Oncology Translational Research and focusing on clinical biomarker development and understanding disease mechanisms. Earlier roles include Associate Director and Director at Reyoung Pharmaceutical Co., Ltd. from March 2012 to March 2017, managing targeted therapy projects and biological lab teams, and a position as Scientist at Pfizer from August 2010 to March 2012, leading drug discovery projects and a research team. Haopeng Rui holds a Ph.D. in Microbiology and Immunology from Harvard Medical School and a Ph.D. in Biochemical Engineering from East China University of Science and Technology.
This person is not in any teams
This person is not in any offices
D3 Bio
1 followers
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated. They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path. D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.” D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.